35024199|t|Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota.
35024199|a|Introduction: Honokiol (HO) exerts neuroprotective effects in several animal models of Alzheimer's disease (AD), but the poor dissolution hampers its bioavailability and therapeutic efficacy. Objectives: A novel honokiol nanoscale drug delivery system (Nano-HO) with smaller size and excellent stability was developed in this study to improve the solubility and bioavailability of HO. The anti-AD effects of Nano-HO was determined. Methods: Male TgCRND8 mice were daily orally administered Nano-HO or HO at the same dosage (20 mg/kg) for 17 consecutive weeks, followed by assessment of the spatial learning and memory functions using the Morris Water Maze test (MWMT). Results: Our pharmacokinetic study indicated that the oral bioavailability was greatly improved by Nano-HO. In addition, Nano-HO significantly improved cognitive deficits and inhibited neuroinflammation via suppressing the levels of TNF-alpha, IL-6 and IL-1beta in the brain, preventing the activation of microglia (IBA-1) and astrocyte (GFAP), and reducing beta-amyloid (Abeta) deposition in the cortex and hippocampus of TgCRND8 mice. Moreover, Nano-HO was more effective than HO in modulating amyloid precursor protein (APP) processing via suppressing beta-secretase, as well as enhancing Abeta-degrading enzymes like neprilysin (NEP). Furthermore, Nano-HO more markedly inhibited tau hyperphosphorylation via decreasing the ratio of p-Tau (Thr 205)/tau and regulating tau-related apoptosis proteins (caspase-3 and Bcl-2). In addition, Nano-HO more markedly attenuated the ratios of p-JNK/JNK and p-35/CDK5, while enhancing the ratio of p-GSK-3beta (Ser9)/GSK-3beta. Finally, Nano-HO prevented the gut microflora dysbiosis in TgCRND8 mice in a more potent manner than free HO. Conclusion: Nano-HO was more potent than free HO in improving cognitive impairments in TgCRND8 mice via inhibiting Abeta deposition, tau hyperphosphorylation and neuroinflammation through suppressing the activation of JNK/CDK5/GSK-3beta signaling pathway. Nano-HO also more potently modulated the gut microbiota community to protect its stability than free HO. These results suggest that Nano-HO has good potential for further development into therapeutic agent for AD treatment.
35024199	0	13	Nano-Honokiol	Chemical	-
35024199	30	48	cognitive deficits	Disease	MESH:D003072
35024199	60	64	mice	Species	10090
35024199	68	87	Alzheimer's disease	Disease	MESH:D000544
35024199	103	117	neuropathology	Disease	MESH:D009422
35024199	163	171	Honokiol	Chemical	MESH:C005499
35024199	173	175	HO	Chemical	MESH:C005499
35024199	236	255	Alzheimer's disease	Disease	MESH:D000544
35024199	257	259	AD	Disease	MESH:D000544
35024199	361	369	honokiol	Chemical	MESH:C005499
35024199	402	409	Nano-HO	Chemical	-
35024199	530	532	HO	Chemical	MESH:C005499
35024199	543	545	AD	Disease	MESH:D000544
35024199	557	564	Nano-HO	Chemical	-
35024199	603	607	mice	Species	10090
35024199	639	646	Nano-HO	Chemical	-
35024199	650	652	HO	Chemical	MESH:C005499
35024199	917	924	Nano-HO	Chemical	-
35024199	939	946	Nano-HO	Chemical	-
35024199	970	988	cognitive deficits	Disease	MESH:D003072
35024199	1003	1020	neuroinflammation	Disease	MESH:D000090862
35024199	1051	1060	TNF-alpha	Gene	21926
35024199	1062	1066	IL-6	Gene	16193
35024199	1071	1079	IL-1beta	Gene	16176
35024199	1134	1139	IBA-1	Gene	114737
35024199	1156	1160	GFAP	Gene	14580
35024199	1190	1195	Abeta	Gene	11820
35024199	1249	1253	mice	Species	10090
35024199	1265	1272	Nano-HO	Chemical	-
35024199	1297	1299	HO	Chemical	MESH:C005499
35024199	1314	1339	amyloid precursor protein	Gene	11820
35024199	1410	1415	Abeta	Gene	11820
35024199	1439	1449	neprilysin	Gene	17380
35024199	1451	1454	NEP	Gene	17380
35024199	1470	1477	Nano-HO	Chemical	-
35024199	1622	1631	caspase-3	Gene	12367
35024199	1636	1641	Bcl-2	Gene	12043
35024199	1657	1664	Nano-HO	Chemical	-
35024199	1706	1709	JNK	Gene	26419
35024199	1710	1713	JNK	Gene	26419
35024199	1718	1722	p-35	Gene	16159
35024199	1723	1727	CDK5	Gene	12568
35024199	1760	1769	GSK-3beta	Gene	56637
35024199	1777	1786	GSK-3beta	Gene	56637
35024199	1797	1804	Nano-HO	Chemical	-
35024199	1855	1859	mice	Species	10090
35024199	1894	1896	HO	Chemical	MESH:C005499
35024199	1910	1917	Nano-HO	Chemical	-
35024199	1944	1946	HO	Chemical	MESH:C005499
35024199	1960	1981	cognitive impairments	Disease	MESH:D003072
35024199	1993	1997	mice	Species	10090
35024199	2013	2018	Abeta	Gene	11820
35024199	2060	2077	neuroinflammation	Disease	MESH:D000090862
35024199	2116	2119	JNK	Gene	26419
35024199	2120	2124	CDK5	Gene	12568
35024199	2125	2134	GSK-3beta	Gene	56637
35024199	2154	2161	Nano-HO	Chemical	-
35024199	2255	2257	HO	Chemical	MESH:C005499
35024199	2286	2293	Nano-HO	Chemical	-
35024199	2364	2366	AD	Disease	MESH:D000544
35024199	Association	11820	17380
35024199	Association	MESH:C005499	17380
35024199	Negative_Correlation	MESH:C005499	MESH:D000544
35024199	Association	MESH:D000090862	12568
35024199	Association	MESH:D000090862	16193
35024199	Negative_Correlation	MESH:D000090862	21926
35024199	Association	MESH:D000090862	16176

